• 1. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 4. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 5. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Benzimidazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles

Recent Advances in the Study of 4,6-Difluoro-1H-benzodimidazol-2(3H)-one (CAS: 1221793-66-3)

4,6-Difluoro-1H-benzodimidazol-2(3H)-one (CAS: 1221793-66-3) is a fluorinated benzimidazole derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug discovery and development. Recent studies have explored its utility as a key intermediate in the synthesis of novel therapeutic agents, particularly in the areas of oncology and infectious diseases. This research briefing provides an overview of the latest findings related to this compound, highlighting its chemical properties, biological activities, and potential clinical applications.

One of the most notable advancements in the study of 4,6-Difluoro-1H-benzodimidazol-2(3H)-one is its role in the development of kinase inhibitors. Kinases are critical targets in cancer therapy, and the fluorinated benzimidazole scaffold has been shown to enhance the binding affinity and selectivity of these inhibitors. Recent publications have demonstrated that derivatives of this compound exhibit potent inhibitory activity against a range of kinases, including those implicated in tumor growth and metastasis. These findings suggest that 4,6-Difluoro-1H-benzodimidazol-2(3H)-one could serve as a valuable building block for the design of next-generation anticancer drugs.

In addition to its applications in oncology, 4,6-Difluoro-1H-benzodimidazol-2(3H)-one has also been investigated for its antimicrobial properties. Studies have revealed that this compound and its derivatives exhibit broad-spectrum activity against both Gram-positive and Gram-negative bacteria, as well as certain fungal pathogens. The mechanism of action appears to involve interference with microbial DNA replication and cell wall synthesis, making it a promising candidate for the development of new antibiotics. Researchers are currently optimizing the chemical structure to improve its pharmacokinetic profile and reduce potential toxicity.

Another area of interest is the use of 4,6-Difluoro-1H-benzodimidazol-2(3H)-one in the synthesis of fluorescent probes for biological imaging. The fluorinated benzimidazole core provides a unique photophysical profile, enabling the development of probes with high sensitivity and specificity for detecting cellular processes. Recent work has focused on tailoring these probes for real-time imaging of enzyme activity and protein-protein interactions, which could have significant implications for both basic research and diagnostic applications.

Despite these promising developments, challenges remain in the practical application of 4,6-Difluoro-1H-benzodimidazol-2(3H)-one. Issues such as solubility, stability, and bioavailability need to be addressed to fully realize its potential in drug development. Ongoing research is exploring various formulation strategies, including nanoparticle-based delivery systems, to overcome these limitations. Furthermore, toxicological studies are being conducted to ensure the safety of this compound and its derivatives for clinical use.

In conclusion, 4,6-Difluoro-1H-benzodimidazol-2(3H)-one (CAS: 1221793-66-3) represents a versatile and promising scaffold in chemical biology and pharmaceutical research. Its applications span from kinase inhibitors and antimicrobial agents to fluorescent probes, highlighting its broad utility. As research continues to uncover new insights into its properties and mechanisms of action, this compound is poised to play a pivotal role in the development of innovative therapeutics and diagnostic tools. Future studies will likely focus on optimizing its chemical derivatives and exploring novel applications in emerging fields such as personalized medicine and targeted therapy.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)